Sunday, October 18, 2020 2:47:46 PM
https://ojrd.biomedcentral.com/articles/10.1186/s13023-020-01514-5
It's not that hard to google. There's a reason this sector is unregulated and has a lot of money thrown via grants. This is prolly the primary reason a pink sheets company even got the license to begin with, no one wants to do it. Paul should be able to negotiate with a university to conduct the trials + the university to get a grant from the NIH or FDA.
It's not that hard to google. There's a reason this sector is unregulated and has a lot of money thrown via grants. This is prolly the primary reason a pink sheets company even got the license to begin with, no one wants to do it. Paul should be able to negotiate with a university to conduct the trials + the university to get a grant from the NIH or FDA.
Recent CUBT News
- Curative Biotechnology Advances Translational Ophthalmology Program Through PennVet Research Agreement • GlobeNewswire Inc. • 05/07/2026 11:00:00 AM
- Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply of Metformin Topical Ophthalmic Therapy • GlobeNewswire Inc. • 04/15/2026 12:08:00 PM
- Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting • GlobeNewswire Inc. • 03/23/2026 11:05:00 PM
- Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting • GlobeNewswire Inc. • 03/23/2026 11:00:00 AM
- Curative Biotechnology Announces Canadian Patent Allowance • GlobeNewswire Inc. • 01/23/2026 01:45:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 12/22/2025 06:40:01 PM
- Curative Biotechnology, Inc. Announces Letter to Shareholders • GlobeNewswire Inc. • 11/18/2025 01:15:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/01/2025 08:07:47 PM
